HALOZYME THERAPEUTICS INC (HALO) Stock Institutional Trading Activity
HALOZYME THERAPEUTICS INC (HALO) position changes reported by tracked institutional filers across multiple SEC 13F reporting periods. Based on recent SEC 13F filings (Q4 2025), investors with some of the largest reported share count changes include Renaissance Technologies LLC, Hancock Classic Value, Sequoia Financial Advisors, Torray Fund, and First Eagle U.S. Value. Explore insights into buying and selling patterns, position changes, and investment conviction levels to understand institutional trading behavior and market dynamics.
Explore more:
- HALOZYME THERAPEUTICS INC (HALO) stock institutional ownership
- HALOZYME THERAPEUTICS INC (HALO) stock insider trading activity
- Stock rankings
| Portfolio quarter | Name | Type | Quantity | Remaining | Reported stock balance |
|---|---|---|---|---|---|
| Q2 2019 | Torray Fund | Sell | -5,584 | 46,243 | $794 |
| Q2 2019 | Renaissance Technologies LLC | Sell | -290,800 | 458,600 | $7,879 |
| Q1 2019 | Renaissance Technologies LLC | Buy | 444,800 | 749,400 | $12,065 |
| Q1 2019 | First Eagle U.S. Value | Sell | -2,500 | 2,128,275 | $34,265 |
| Q4 2018 | Torray Fund | Buy | 7,951 | 51,827 | $758 |
| Q4 2018 | Miller Value Partners | Sell | -150,000 | 20,000 | $293 |
| Q4 2018 | Renaissance Technologies LLC | Sell | -286,000 | 304,600 | $4,456 |
| Q4 2018 | First Eagle U.S. Value | Sell | -42,314 | 2,130,775 | $31,173 |
| Q3 2018 | Torray Fund | Buy | 6,324 | 43,876 | $797 |
| Q3 2018 | Renaissance Technologies LLC | Sell | -302,800 | 590,600 | $10,731 |
| Q3 2018 | First Eagle U.S. Value | Buy | 48,526 | 2,173,089 | $39,485 |
| Q2 2018 | Torray Fund | Sell | -1,488 | 37,552 | $634 |
| Q2 2018 | First Eagle U.S. Value | Sell | -880,190 | 2,124,563 | $35,841 |
| Q1 2018 | Torray Fund | Buy | 452 | 39,040 | $765 |
| Q1 2018 | Renaissance Technologies LLC | Buy | 156,800 | 893,400 | $17,502 |
| Q1 2018 | First Eagle U.S. Value | Sell | -1,526,328 | 3,004,753 | $58,863 |
| Q4 2017 | Torray Fund | Buy | 8,643 | 38,588 | $782 |
| Q4 2017 | Renaissance Technologies LLC | Buy | 721,900 | 736,600 | $14,924 |
| Q4 2017 | First Eagle U.S. Value | Sell | -1,913,900 | 4,531,081 | $91,800 |
| Q3 2017 | Torray Fund | Buy | 258 | 29,945 | $520 |
| Q3 2017 | Miller Value Partners | Sell | -779,800 | 170,000 | $2,953 |
| Q3 2017 | First Eagle U.S. Value | Sell | -949,334 | 6,444,981 | $111,949 |
| Q2 2017 | Torray Fund | Sell | -1,099 | 29,687 | $381 |
| Q2 2017 | Miller Value Partners | Buy | 949,800 | 949,800 | $12,176 |
| Q1 2017 | Torray Fund | Sell | -29,333 | 30,786 | $399 |
| Q1 2017 | First Eagle U.S. Value | Sell | -293,200 | 7,394,315 | $95,830 |
| Q4 2016 | Torray Fund | Buy | 60,119 | 60,119 | $594 |
| Q4 2016 | Renaissance Technologies LLC | Sell | -85,300 | 14,700 | $145 |
| Q4 2016 | First Eagle U.S. Value | Buy | 292,015 | 7,687,515 | $75,953 |
| Q3 2016 | Renaissance Technologies LLC | Sell | -275,000 | 100,000 | $1,208 |
Frequently asked questions about HALO activity
Which institutional owners are buying HALO?
Institutional owners buying HALO include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.
What does "buy" mean in HALO activity?
"Buy" means an investor increased their reported position in HALO compared to the prior reporting period. This reflects growing exposure to HALOZYME THERAPEUTICS INC (HALO) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).
Is institutional interest in HALO increasing?
Institutional interest in HALO can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.